

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE LICENSING AGREEMENT OF SIM0278 WITH ALMIRALL S.A. FOR RIGHTS OUTSIDE GREATER CHINA

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that, on September 28, 2022, the Group has entered into a licensing agreement (the “**Agreement**”) with Almirall S.A. (“**Almirall**”), a global biopharmaceutical company. Under the Agreement, the Group granted Almirall an exclusive right to develop and commercialize SIM0278 (the “**Product**”), an autoimmune drug candidate, outside of Greater China (the “**Territory**”).

Within the terms of the Agreement, the Group shall receive a US\$15 million upfront payment and up to US\$492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon future sales of the Product in the Territory from Almirall. The Group will retain all rights to the Product in Greater China.

ABOUT SIM0278

SIM0278 is an interleukin 2 mutant fusion protein (IL-2 mu Fc) that activates regulatory T cells developed in-house by utilizing the Group’s protein engineering platform. This IND ready subcutaneous injection will potentially be developed to treat various autoimmune diseases. SIM0278 exhibits improved PK profile and selective activation of Treg cells with no activation of effector T cells or NK cells to restore immune balance which has been demonstrated in multiple preclinical disease models.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The Company focuses on three therapeutic areas, oncology, central nervous system and autoimmune diseases, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future”. Leveraging its R&D capability and commercialization excellence, the Company has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a top strategic cooperation partner with world leading innovative companies and research institutes.

ABOUT ALMIRALL

Almirall is a global biopharmaceutical company focused on skin health. The company collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Almirall’s Noble Purpose is at the core of their work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Almirall invests in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need. Almirall, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70 countries.

LISTING RULES IMPLICATIONS

The entering into of the Agreement does not constitute a notifiable transaction under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) as the transactions contemplated under the Agreement are of revenue nature in the ordinary and usual course of business of the Group.

To the best of the knowledge, information and belief, having made all reasonable enquiries by the Directors of the Company, Almirall and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Listing Rules).

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, September 29, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong and Mr. WAN Yushan as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.